Title A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe III) /
Authors Atkinson, Victoria G ; Quaglino, Pietro ; Aglietta, Massimo ; Del Vecchio, Michele ; Depenni, Roberta ; Consoli, Francesca ; Bafaloukos, Dimitrios ; Ferrucci, Pier Francesco ; Tulytė, Skaistė ; Krajsová, Ivana ; Ascierto, Paolo A ; Gueli, Rossana ; Arance, Ana ; Gogas, Helen ; Banerjee, Hiya ; Saliba, Teddy ; de Jong, Egbert ; Neyns, Bart
DOI 10.3390/cancers13102466
Full Text Download
Is Part of Cancers.. Basel : MDPI AG. 2021, vol. 13, no. 10, art. no. 2466, p. [1-13].. eISSN 2072-6694
Keywords [eng] BRAF V600 ; chart review ; dabrafenib ; melanoma ; real-world ; trametinib
Abstract [eng] The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable longterm efficacy in patients with BRAF V600–mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study in patients with unresectable or metastatic melanoma treated with dab monotherapy and/or dab + tram combination therapy as part of the Named Patient Program or Individual Patient Program. Overall, 509 patients were enrolled. Patients were categorized into three groups based on their observed treatment duration: long-term (on therapy ≥12 months), intermediate (on therapy ≥6 months and <12 months), and short-term (on therapy <6 months) duration of benefit. More patients in the short-term duration of benefit group had baseline characteristics associated with poor prognosis compared with the other two groups. Median lactate dehydrogenase (LDH) levels (368 U/L) at baseline were also higher in the short-term duration of benefit group. No new safety signals were identified. DESCRIBE III identified baseline characteristics associated with long-term benefit of dab + tram. Lower LDH level and <3 metastatic sites at baseline were associated with a longer duration of benefit, confirming that the findings from COMBI-d and COMBI-v are relevant to patients treated in a real-world setting.
Published Basel : MDPI AG
Type Journal article
Language English
Publication date 2021
CC license CC license description